LENZ
NASDAQ HealthcareLENZ Therapeutics, Inc. - Common Stock
Biotechnology
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
�� 市场数据
| 价格 | $10.18 |
|---|---|
| 成交量 | 565,684 |
| 市值 | 319.19M |
| 贝塔系数 | 2.290 |
| RSI（14日） | 72.0 超买 |
| 200日均线 | $25.80 |
| 50日均线 | $11.40 |
| 52周最高 | $50.40 |
| 52周最低 | $8.25 |
| Forward P/E | -3.86 |
| Price / Book | 1.12 |
🎯 投资策略评分
LENZ 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (99/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 💰 Dividend Daddy (3/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 LENZ in your text
粘贴任何文章、记录或帖子 — 工具将提取 LENZ 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.